CHEMOPREVENTION in BREAST CANCER
|
|
- Gwen McDaniel
- 6 years ago
- Views:
Transcription
1 CHEMOPREVENTION in BREAST CANCER Ozlem Er, M.D. Assc Prf f Medical Onclgy ESMO Curse Essentials f Medical Onclgy
2 Outline Risk Assessment Mlecular Targets ER psitive Breast Cancer Tamxifen Ralxifene Lasfxifene Armatase Inhibitrs ER negative Breast Cancer Retinids Lapatinib Metfrmin ASCO 2009 Guideline
3 Essential Elements fr Breast Cancer Preventin Trials Ppulatin with defined, quantifiable risk Gail mdel NCI Breast Cancer Risk Assessment Tl A reasnable target An acceptable interventin A measurable endpint Reductin in BC incidence Bimarker mdulatin
4 NCI Breast Cancer Risk Assessment Tl
5 Gail Mdel Prjecting individualized prbabilities f develping breast cancer fr white females wh are being examined annually T assist in medical cunseling, a methd t estimate the chance that a wman with given age and risk factrs will develp breast cancer ver a specified interval. The risk factrs used were age at menarche, age at first live birth, number f previus bipsies, number f first-degree relatives with breast cancer. Gail MH, et al. J Natl Cancer Inst. 1989
6 Appraches t Preventin Lifestyle factrs Diet Weight cntrl Exercise Reprductive factrs Exgenus hrmnes Chempreventin Surgical preventin
7 Management Plan Age Family histry Prir bipsy & histlgic results Fertility histry
8 Functinal Characterizatin Of Mlecular Targets Fr Breast Cancer Therapy Tamxifen -Five years f tamxifen (20 mg/d) - Wmen at increased risk f breast cancer t reduce their risk f ER psitive invasive breast cancers fr up t 10 years. -The benefit f taking tamxifen fr mre than 5 years is unknwn. -The greatest clinical benefit and the fewest side effects were derived frm the use f tamxifen in yunger (premenpausal) wmen 35 t 50 years f age wh are unlikely t experience thrmbemblic sequelae r uterine cancer, wmen withut a uterus, and wmen at high risk f breast cancer.
9 Tamxifen Preventin Trials Fur phase III randmized trials have prspectively evaluated tamxifen cmpared with placeb fr breast cancer risk reductin NSABP-P1 IBIS-I Ryal Marsden Tamxifen Preventin Trial Italian Randmized Tamxifen Preventin Trial
10 NSABP-P1 13,388 wmen 35 years r lder wh were at increased risk f breast cancer (ie, 35 t 59 years f age with a 1.66 risk using a mdified Gail mdel, 60 years ld, r with prir LCIS) Wmen were excluded if they were using HT, ral cntraceptives r andrgens, r if they had used these 3 mnths befre randmizatin. Placeb r tamxifen (20 mg/d) fr 5 years The initial results were based n a median f 4.6 years f fllwup. Invasive BC 89 vs 175 RR reductin f 49% Abslute risk reductin f 15 invasive breast cancers per 1,000 wmen Nninvasive cancers 50% reductin Abslute risk reductin f six invasive breast cancers per 1,000 wmen Fewer ER-psitive tumrs 41 vs 130 Overall RR reductin f 69% Reductin f 16 ER-psitive breast cancers per 1,000 wmen The incidence f ER negative tumrs was similar between grups, 38 vs 31 Fisher B, et al. JNCI 1998
11 NSABP-P1: 7 yr fllwup The reductin in bth invasive (RR 0.57) and nninvasive (RR 0.63) BC persisted. 250 invasive breast cancers vs nninvasive breast cancers vs 60 N statistically significant difference in stage distributin f invasive BC between the tw grups. There was a reductin in ER+ tumrs f 62% in the tamxifen grup (RR 0.38) 70 vs 182 N statistically significant difference in ER-negative tumrs (RR1.31). Tamxifen cnsistently reduced invasive BC risk, particularly ER-psitive tumrs, in all age strata, all 5-year predicted risk strata fr breast cancer (beginning at1.66%), and wmen with atypical hyperplasia (AH) r a histry f LCIS. The magnitude f the prtective benefit in the updated results was similar t the initial reprt. NSABP-P1 trial unblinded participants in 1998, with subsequent differential rates f withdrawal frm the placeb arm versus the treatment arm, and crss-ver frm the placeb arm t the tamxifen arm. These circumstances may have biased the reprted estimates f benefits and risks tward the null Fisher B, et al. JNCI 2005
12 IBIS-I 7,154 wmen age 35 t70 years, wh were at increased risk f BC, t receive either tamxifen (20 mg/d) r placeb fr 5 years Abslute risk reductin f 15 breast cancers per 1,000 wmen N difference in the risk f ER-negative invasive tumrs (35 in each grup) The risk f ER-psitive invasive BC 34% lwer in the tamxifen arm (87 cases v 132 cases) Abslute risk reductin f 13 ER-psitive breast cancers per 1,000 wmen A decrease in DCIS but nt statistically significant (17 wmen n tamxifen with DCIS cmpared with 27 wmen n placeb). These fllw-up results suggest that the risk-reducing effect f tamxifen persists fr at least 10 years. Cuzick J, et al. JNCI 2007
13 Ryal Marsden Tamxifen Preventin Trial 2,494 healthy wmen age 30 t 70 years t receive tamxifen (20 mg/d) r placeb fr 8 years. Initial results shwed n effect f tamxifen n the incidence f breast cancer. With a median f 13.2 years f fllw-up and a maximum f 20 years, als shwed n statistically significant effect f tamxifen n the verall incidence f breast cancer There was als n statistically significant difference in the incidence f invasive BC The incidence f ER-psitive invasive BC was 39% lwer in the tamxifen grup ver the entire perid, (53 vs 86 wmen) Abslute reductin f 26 ER-psitive BC per 1,000 wmen ver the 13.2 years median fllw-up perid There was n effect f tamxifen n the incidence f ER-psitive BC during active treatment The variable benefit f tamxifen in reducing the incidence f ER-psitive BC during and after treatment in this study is likely a reflectin f a small sample size rather than a meaningful difference when cmpared with the benefits bserved in the NSABP-P1 and IBIS-I studies. Pwles TJ, et al. JNCI 2007
14 Italian Randmized Tamxifen Preventin Trial 5,408 wmen age 35 t 70 years with a prir hysterectmy and n prespecified breast cancer risk t receive tamxifen (20 mg/d) r placeb fr 5 years. Their breast cancer risk was lwer than that f the general ppulatin, because 48% f participants had undergne a bilateral phrectmy. N statistically significant reductin in verall breast cancer risk bserved in the tamxifen grup 62 vs 74 A statistically significant reductin in prgesterne receptr psitive tumrs 27 vs 44 A reductin in breast cancer risk amng wmen at high risk with at least ne vary intact N effect f tamxifen n ER-negative breast cancer Vernesi U, et al. JNCI 2007
15 Meta-analysis f the Primary Results f the Fur Tamxifen Preventin Trials Overview f the main utcmes in breast-cancer preventin trials The cmbined reductin in breast cancer incidence (invasive and DCIS) with tamxifen use cmpared with placeb ranged frm a relative risk f 34% t 38% There was n reductin in the risk f ER-negative BC The incidence f ER-psitive BC decreased by 48% Age had n apparent effect n the relative degree f BC risk reductin. Cuzick J, et al.lancet 361: 2003
16 Adverse Events and Side Effects Related t Tamxifen Use Endmetrial cancer (grade I adencarcinma) Thrmbemblic events (PE, DVT, retinal v thrmbsis) Strke Cataracts Cgnitin (incnclusive) Gyneclgic and vasmtr symptms (vaginal discharge) Fractures Mrtality N verall effect f tamxifen n all-cause mrtality PE was the nly cause f death shwing an increase with tamxifen use Nne f the preventin trials have demnstrated an effect f tamxifen n breast cancer specific mrtality
17 Ralxifene Fr pstmenpausal wmen at increased risk fr BC, ralxifene (60 mg/d) fr 5 years may be ffered as anther ptin t reduce the risk f ER psitive invasive BC. Equally efficacius t tamxifen in reducing BC risk in pstmenpausal wmen. Nt as effective in reducing the incidence f nninvasive BC cmpared with tamxifen In the STAR trial, ralxifene was assciated with a mre favrable side-effect prfile cmpared with tamxifen, including a statistically significant lwer risk f thrmbemblic disease, benign uterine cmplaints, and cataracts as cmpared with tamxifen. Nt knwn t have an effect n verall r breast cancer specific mrtality in wmen at increased risk f BC Ralxifene may be used fr lnger than 5 years in wmen with steprsis in whm BC risk reductin is an additinal ptential benefit.
18 Ralxifene Fur randmized prspective trials have evaluated the influence f ralxifene n breast cancer risk. Risk reductin was the primary end pint f tw trials, STAR and RUTH trials, A secndary end pint f the MORE trial. Als the primary end pint f the CORE trial, which fllwed a subgrup f participants frm the MORE trial.
19 MORE and CORE Trials 7,705 pstmenpausal wmen with steprsis wh were <=80 years f age Ralxifene (60 r 120 mg/d) r placeb fr 4 years. Participants were entered regardless f BC risk, which was nt frmally assessed at study entry, althugh infrmatin n breast cancer family histry was cllected and presented. Breast cancer was a secndary utcme. 78 cases f BC in 7,682 wmen (44/2571 placeb vs 34/ 5111 Ralxifene) 59 were invasive BC and 19 were nninvasive. Wmen treated with ralxifene had a statistically significant reduced risk f invasive BC cmpared with wmen n placeb particularly ER psitive invasive BC
20 MORE and CORE Trials After the cmpletin f the MORE trial, cnsenting participants were bserved under an amended design called the CORE trial, which recnsented 4,011 MORE trial participants (52%) CORE participants had 5-year breast cancer risk assessed at study entry with the Gail mdel. 4 years f additinal ralxifene use reduced invasive BC by 59% cmpared with placeb and ER-psitive invasive BC by 66% cmpared with placeb. Thrugh 8 years f randmizatin frm the MORE trial t the end f the CORE trial, ralxifene cntinued t significantly reduce the risk f verall BC, invasive BC, and ERpsitive BC The incidence f ERnegative invasive BC was similar in the tw treatment grups thrughut the 8 years f treatment
21 RUTH Ralxifene (60 mg/d) vs placeb in 10,101 pstmenpausal wmen with crnary heart disease r multiple risk factrs fr crnary heart disease. The tw primary utcme measures were crnary events and invasive BC. Participants were entered regardless f BC risk, and nly 41% had a 5-year predicted BC risk f 1.66%. Nt influence the risk f primary crnary events Significantly reduced invasive BC risk primarily due t reduced ERpsitive BC
22 NSABP STAR 19,747 pstmenpausal wmen with a 5-year increased risk f BC Tamxifen (20 mg/d) r ralxifene (60 mg/d) fr 5 years. The same risk assessment used in NSABP-P1. The primary end pint was a reductin in BC risk. Baseline characteristics were substantially different frm the prir NSABP-P1 tamxifen preventin trial. 5-year prjected breast cancer risk was higher (58.7% had a 3% 5-year prjected breast cancer risk in the STAR trial, cmpared with 44% in the NSABP-P1 trial). Mre than 51% f STAR participants had a prir hysterectmy as cmpared with 37% f participants in the NSABP-P1 tamxifen preventin trial. Mre than 32% f STAR participants had a histry f breast LCIS r AH cmpared with 15% f NSABP-P1 participants. The incidence f invasive breast cancer in the tamxifen and ralxifene grups were nt significantly different. Mre nninvasive breast cancers in the ralxifene (n80) grup than in the tamxifen (n57) grup, nt statistically significant. Findings were als cmparable fr wmen diagnsed with ER-psitive tumrs
23 Adverse Events and Side Effects Related t Ralxifene Use Endmetrial cancer (Tmx > Ral) VTE (Tmx > Ral) Ischemic Heart Disease (n increase) (Tmx= Ral) Strke (wmen with underlying vascular disease shuld nt be treated with ralxifene) Cataracts (n increase) Cgnitin (incnclusive) Gyneclgic and vasmtr symptms (Tmx > Ral) Fractures (reduced) Mrtality N effect f ralxifene n the incidence f death in these trials Nne f the preventin trials have demnstrated an effect f ralxifene n breast cancer specific mrtality
24 Lasfxifene Third generatin SERM The randmised, placeb-cntrlled Pstmenpausal Evaluatin and Risk-Reductin With Lasfxifene (PEARL) study 8,556 therwise healthy wmen aged 59 t 80 years 0.5 mg/day vs placeb r 0.25 mg/day vs placeb, fr 5 years The primary endpints were incidence f estrgen receptr-psitive (ER+) breast cancer and vertebral fracture (at 3 years) and nnvertebral fracture (at 5 years) Increased prtectin against BC in pstmenpausal wmen with steprsis and a high risk f BC Pwles T, et al. St Gallen 2009
25 SERMs in the Preventin f Breast Cancer 35% reductin in BC 53% reductin in ER+ BC Cuzick J. SABCS, 2009
26 Adverse Events and Side Effects Related t SERM Use Inc endmetrial cancer (Tmx) N effect n clrectal, varian r ther cancer Inc DVT, PE & retinal vein thrmbsis Dec fractures (Las) Inc hysterectmy (Tmx) N effect n mrtality, incidence f strke, TIA, MI, cataract Cuzick J. SABCS, 2009
27 Armatase Inhibitrs The effects f armatase inhibitrs (anastrzle, letrzle) and inactivatrs (exemestane) n cntralateral BC risk supprt further evaluatin f these agents fr BC risk reductin. A meta-analysis f adjuvant breast cancer trials evaluating armatase inhibitrs identified a 48% relative reductin in cntralateral BC risk with five f the six cmparatrs being tamxifen. Cuzick J. J Clin Oncl, 2005
28 Cntralateral Tumrs in AI Trials Cuzick J. SABCS, 2009
29 Armatase Inhibitrs The cncept f using armatase inhibitrs as a BC risk reductin agent was strengthened by the recent update f the ATAC trial, in which, with 100 mnths f fllw-up, 5 years f anastrzle was assciated with fewer cntralateral breast cancers as a first event cmpared with 5 years f tamxifen (fr hrmne receptr psitive patients) Frbes JF, et al. Lancet Oncl, 2008
30 IBIS-II 6,000 pstmenpausal wmen at increased breast cancer risk t 5 years f placeb r anastrzle (1 mg/d)
31 ExCel 4560 pstmenpausal wmen either at increased BC risk r age 60 years t 5 years f exemestane (25 mg/d) r placeb
32 Direct Effects f Hrmnal Manipulatin
33 Preventin f ER-negative Breast Cancer
34 ER-Negative Breast Cancer All f the breast cancer risk reductin trials using SERMs demnstrate that these agents are effective in reducing the risk f nly ERpsitive breast cancer. They d nt prevent the develpment f ERnegative breast cancer, which accunts fr 30% f all breast cancers Tamxifen did, hwever, seem t increase the sensitivity f mammgraphy fr the detectin f ER-negative tumrs in the NSABP-P1 trial. ERnegative tumrs were fund earlier and were smaller in wmen treated with tamxifen in cmparisn with wmen n placeb. There is a need t develp agents that als prevent ER negative breast cancer.
35 ER-Negative Breast Cancer Several classes f chempreventive agents have been shwn t prevent ER-negative breast cancer in animal mdels. Retinids and rexinids (9-cis retinic acid, bexartene, and LG100268), Cx-2 inhibitr (celecxib) Tyrsine kinase inhibitrs (gefitinib and lapatinib). Several f these agents are nw being tested in early-phase risk reductin trials invlving bimarker mdulatin. In the future, these cancer risk reductin drugs will be cmbined with hrmnal agents (such as SERMs r armatase inhibitrs) t reduce the risk fr bth ER-psitive and ER-negative breast cancer.
36 Retinids Fenretinide is the nly retinid that has been evaluated in a phase III study fr secndary BC preventin. 3,000 wmen age 30 t 70 years with a diagnsis f DCIS r stage I BC 5 years f fenretinide (200 mg/d) r n treatment, in additin t standard tx The primary end pint f this study was the incidence f secnd BC At a median fllw-up time f 97 mnths, there was n statistically significant difference in verall BC incidence between the tw arms. Further fllw-up f a subset f wmen (59%) ver a median f almst 15 years cntinued t bserve n difference in verall BC incidence between the tw grups. In a subset analysis, a statistically significant reductin in secnd primary BC was bserved amng the premenpausal wmen treated with fenretinide N difference was bserved in verall mrtality between the study arms. Dermatlgic and dark-visin adaptatins were the mst cmmn adverse events. Nw being studied in cmbinatin with tamxifen fr the preventin f BC in high-risk wmen. (J Clin Oncl 24: , 2006)
37 ER-Negative Breast Cancer New subclassificatin scheme fr ERnegative breast cancer based upn kinmewide gene expressin prfiling, ptentially relevant fr bth treatment and clinical utcme. Speers et al. Clin Cancer Res 2009
38 Lapatinib
39 Lapatinib
40 Metfrmin Managing breast cancer with a diabetes drug? Epidemilgical data: Lwer cancer rates in diabetics taking metfrmin Ptentially better respnse t chemtherapy Plausible bilgic mechanism Grwing preclinical data Animal mdels Increased apptsis in cell culture
41 Metfrmin
42 Metfrmin
43 Metfrmin Preclinical and Clinical Studies
44 ASCO Clinical Practice Guideline Update n the Use f Pharmaclgic Interventins Including Tamxifen, Ralxifene, and Armatase Inhibitin fr Breast Cancer Risk Reductin Visvanathan K, et al. JCO 2009
45 Ozlem Er, M.D. Assc Prf f Medical Onclgy NBC
BRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationThe principles of evidence-based medicine
The principles f evidence-based medicine By the end f this mdule yu shuld be able t: Describe what evidence based medicine is Knw where t find quality evidenced based medicine n the internet Be able t
More informationEvaluation of a Shared Decision Making Intervention between Patients and Providers to Improve Menopause Health Outcomes: Issue Brief
Evaluatin f a Shared Decisin Making Interventin between Patients and Prviders t Imprve Menpause Health Outcmes: Issue Brief Key Findings Tablet technlgy can be successfully incrprated int primary practices
More informationiprex Fact Sheet: Key Results
EMBARGOED UNTIL RELEASE Tuesday, 23 Nvember 2010, 8 a.m. EST CONTACT Mark Aurigemma; 646-270-9451; mark@aucmm.net Pedr Gicchea; 415-490-8350 pgicchea@gladstne.ucsf.edu iprex Fact Sheet: Key Results iprex
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationPage 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided
Page 1 f 5 NSABP B-47 - A Randmized Phase III Trial f Adjuvant Therapy Cmparing Chemtherapy Alne (Six Cycles f Dcetaxel Plus Cyclphsphamide r Fur Cycles f Dxrubicin Plus Cyclphsphamide Fllwed by Weekly
More informationHealth Science Ch. 16 Cancer Lecture Outline
Cancer Leading cause f disease-related death amng peple under age 75 Secnd leading cause f death Evidence supprts that mst cancers culd be prevented by simple lifestyle changes Tbacc is respnsible fr abut
More informationFour categories which guide further evaluation
Unknwn Primary Updated May 2017 by Di Maria Jiang (PGY-5 Medical Onclgy Resident, University f Trnt) Reviewed by Dr. Chistine Elser (Staff Medical Onclgist, University f Trnt) and Dr. Sct Dwden (Staff
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationService Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin
Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)
More informationCONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW
FACT SHEET CONTACT: Amber Hamiltn 212-266-0062 TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW Type 2 diabetes accunts fr 90-95% f the 29.1 millin diabetes cases in the U.S. 1 Obesity is a majr independent
More informationPublic consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking
Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment
More informationBREAST CANCER Updated May 2017 by Dr. Veitch (PGY-5 Medical Oncology Resident, University of Calgary)
BREAST CANCER Updated May 2017 by Dr. Veitch (PGY-5 Medical Onclgy Resident, University f Calgary) Reviewed by Dr. Jan-Willem Henning (Staff Medical Onclgist, Tm Baker Cancer Centre, University f Calgary),
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationPBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More information2. How are screening and diagnostic mammograms different?
Mammgrams cmprises public dmain material frm the Natinal Cancer Institute at the Natinal Institutes f Health, an agency f the U.S. Department f Health and Human Services. Mammgrams Key Pints A mammgram
More informationBREAST CANCER Updated June 2016 by Dr. Nixon (PGY-5 Medical Oncology Resident, University of Calgary)
BREAST CANCER Updated June 2016 by Dr. Nixn (PGY-5 Medical Onclgy Resident, University f Calgary) Reviewed by Dr. Jan-Willem Henning (Staff Medical Onclgist, Tm Baker Cancer Centre, University f Calgary),
More informationTHROUGH 1979, immunosuppressive
Five-Year Survival After Liver Transplantatin THROUGH 1979, immunsuppressive therapy fr liver transplantatin at ur center was with aathiprine (r cyclphsphamide) and sterids, t which antilymphcyte glublin
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationCSP. Estradiol valerate oral tablets. Estradiol hemihydrate Transdermal Patch
CSP Estradil valerate ral tablets Estradil hemihydrate Transdermal Patch 1 Table f Cntents 4.3 Cntraindicatins 4.4. Special warnings and precautins fr use 4.5 Interactins 4.6 Pregnancy and lactatin 4.7
More informationctdna-guided Change of Therapy Improves Quality of Life of a Lung Cancer Patient
CASE STUDY ctdna-guided Change f Therapy Imprves Quality f Life f a Lung Cancer Patient Quick Summary Tripti Vasudev*, aged 61 years, was diagnsed with NSCLC. Genetic analysis revealed the presence f an
More informationReviewed by Dr. Nimira Alimohammed (Staff Oncologist, University of Calgary) and Dr. Scott Berry (Staff Oncologist, University of Toronto) in 2016
PROSTATE CANCER Updated January 2016 by Dr. Kristy Wassn (PGY-5 Medical Onclgy Resident, University f Trnt) and August 2017 by Dr. Jenny K (Staff Onclgist, Abbtsfrd Cancer Centre, BCCA) Reviewed by Dr.
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationPET FORM Planning and Evaluation Tracking ( Assessment Period)
Divisin f: Behaviral Studies PET FORM Planning and Evaluatin Tracking (2010 2011 Assessment Perid) Persn Respnsible fr this Divisin: Jerry Mller Department f: Behaviral Sciences Persn Respnsible fr this
More informationPatterns of Cholesterol Distribution in the Participants of a Screening Project
Patterns f Chlesterl Distributin in the Participants f a Screening Prject Abdul Hamid Shaikh, S With guidelines similar t thse recmmended by the Natinal Chlesterl Educatin Prgram (NCEP), 3,3 individuals
More informationPodcast Transcript Title: Common Miscoding of LARC Services Impacting Revenue Speaker Name: Ann Finn Duration: 00:16:10
Pdcast Transcript Title: Cmmn Miscding f LARC Services Impacting Revenue Speaker Name: Ann Finn Duratin: 00:16:10 NCTCFP: Welcme t this pdcast spnsred by the Natinal Clinical Training Center fr Family
More informationLung cancer. Lung cancer basics
Onclgy cre learning series by Harmesh R. Naik, MD. Lung cancer Lung cancer basics Incidence: A wrldwide epidemic : Mre than 1 millin new cases per year and mre than 900,000 deaths annually. Overall mrtality
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationNonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer
Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationFTD RESEARCH: The Value of Studies and Opportunities for Involvement
FTD RESEARCH: The Value f Studies and Opprtunities fr Invlvement Sarah Lawrence, MS Research Prgram Manager Ann Fishman, MBA Sr. Research Crdinatr Weiyi Mu, ScM Genetic Cunselr Suzanne Dana Spuse/Caregiver
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationA. Catalonia World Health Organization Demonstration Project
A. Catalnia Wrld Health Organizatin Demnstratin Prject In 1989, the Health Department f Catalnia (Spain) and the Cancer Unit at the WHO (Geneva) designed and planned a demnstratin prject fr implementatin
More informationTITLE: Managing Menopausal Symptoms in Breast Cancer Survivors
'.;* * AD GRANT NUMBER: DAMD17-94-J-4507 TITLE: Managing Menpausal Symptms in Breast Cancer Survivrs PRINCIPAL INVESTIGATOR: Patricia A. Ganz, M.D. CONTRACTING ORGANIZATION: University f Califrnia, Ls
More informationMedication Assisted Treatment for Opioid Use Disorder in Rural Colorado
Medicatin Assisted Treatment fr Opiid Use Disrder in Rural Clrad Why is piid use disrder getting s much attentin? Opiid Use Disrder (OUD) has seen an epidemic rise in the United States ver the past decade.
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationAlpelisib in combination with fulvestrant for advanced HR positive, HER2-negative breast cancer in men and postmenopausal women
NIHR Innvatin Observatry Evidence Briefing: Nvember 2017 Alpelisib in cmbinatin with fulvestrant fr advanced HR psitive, HER2-negative breast cancer in men and pstmenpausal wmen NIHRIO (HSRIC) ID: 9191
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationThe research question: What was discovered in the 1940s that could treat syphilis?
Psychlgy B30 Human Sexuality Sexually Transmitted Infectins Tuskegee Syphilis Experiment Ppulatin: The research questin: What was discvered in the 1940s that culd treat syphilis? Hw many men died f syphilis
More informationSUICIDE AND MENTAL ILLNESS IN SINGAPORE
Vl. 15, N. 3. SINGAPORE MEDICAL JOURNAL 191 September, 1974. SUICIDE AND MENTAL ILLNESS IN SINGAPORE By W. F. Tsi and B. H. Chia SYNOPSIS This is a study f 112 cases f suicides wh had a past histry f being
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationNPCR CLINICAL EDIT CHECKS
NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationNCI Version Date: (194) NSABP B-55/BIG 6-13
Figure 1 Study Flw Chart ICF fr patients with unknwn BRCA status t underg central BRCA testing during, r prir t, neadjuvant/adjuvant chemtherapy Neadjuvant chemtherapy Minimum 6 cycles (cntaining anthracyclines,
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationRisk factors in health and disease
Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk
More informationSterilization. B.K. Merritt, MD. Second most common form of birth control after pills. Surgical (tubal ligation or removal)
Sterilizatin B.K. Merritt, MD Overview Secnd mst cmmn frm f birth cntrl after pills Shuld never be cnsidered reversible Mirena IUD and Nexplann implant are bth reversible and are as effective r even mre
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationAdult Preventive Care Guidelines
Adult Preventive Care Guidelines Gundersen is yur partner fr better health. We want t wrk with yu t make sure that yu and yur family are as healthy as pssible. That can be accmplished best if we wrk tgether
More informationHormone Replacement Therapy
Hrmne Replacement Therapy Therapeutics III December 8, 2003 Alicia Frinash, Pharm.D. Required Readings Kalantaridu S, Davis S, Calis K. Hrmne replacement therapy. In: DiPir J, Talbert R, Yee G et al. Pharmactherapy:
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationASSESSMENT OF PITUITARY FUNCTION IN PATIENTS WITH SERUM PROLACTIN LEVELS GREATER THAN 100 NG/ML*t
FERTILITY AND STERILITY Cpyright 1979 The American Fertility Sciety Vl. 32, N.2, August 1979 Printed in U.s.A. ASSESSMENT OF PITUITARY FUNCTION IN PATIENTS WITH SERUM PROLACTIN LEVELS GREATER THAN 100
More informationField Epidemiology Training Program
Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case
More informationThis monograph was prepared by The Ottawa Integrative Cancer Centre (OICC), in collaboration
CAMEO Cmplementary Medicine Educatin & Outcmes Prgram ThismngraphwaspreparedbyTheOttawaIntegrativeCancerCentre(OICC),incllabratin withthecmplementarymedicineeducatinandoutcmes(cameo)researchprgram.itis
More informationEvidence Dossier to support COPD formulary decision making and guideline development
Evidence Dssier t supprt COPD frmulary decisin making and guideline develpment Prescribing and adverse event reprting infrmatin can be fund n the final pages f this dcument. Anr and Ellipta Trademarks
More informationA foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:
RADIOGRAPHY OF THE ANKLE AND FOOT (OTTAWA ANKLE RULES) Clinical Practice Guideline January 2007 This guideline has been adapted frm the Ottawa Ankle Rules develped by Dr. Ian Stiell et al. Dr. Stiell received
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More informationBREAST CANCER RISK REDUCTION
BREAST CANCER RISK REDUCTION Clinical Practice Guideline Update Introduction ASCO published its first breast cancer risk reduction (BCRR) guideline in 1999 ASCO Guidelines are updated at intervals by an
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationPICO question In patients with glomerulonephritis what are patient preferences and values for immunosuppressive and non-immunosuppressive therapy?
KDIGO GN Guideline update Evidence summary Patient preferences fr glmerulnephritis treatment PICO questin In patients with glmerulnephritis what are patient preferences and values fr immunsuppressive and
More informationThe data refer to persons aged between 15 and 54.
Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationTASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE
Sunday 19 July, 2015 TASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE SIX STRATEGIC pririties have tday (Sunday) been recmmended by the Independent Cancer Taskfrce t help
More informationBreast cancer diagnosis and treatment: an update
Breast cancer diagnsis and treatment: an update Epidemilgy Breast cancer is the mst cmmn cancer in the UK. 1 There are apprximately 44,600 wmen and 300 men diagnsed each year in the UK. 1 Mre than 12,000
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationJessica Philpott MD PhD Digestive Diseases Institute Cleveland Clinic
Jessica Philptt MD PhD Digestive Diseases Institute Cleveland Clinic Objectives Review the Crhn s and Clitis Fundatin Challenges t Research Gals 2018 Review data in envirnment and genetics as cntributing
More information1. Re: Randomised prostate cancer screening: 20 year follow-up
1. Re: Randmised prstate cancer screening: 20 year fllw-up Harriet E Burn, Fundatin year 1 dctr Miss Sheila Fraser, and Mr. Sabapathy Balasubramanian Ryal Hallamshire Hspital, Sheffield Dear Editr, We
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationFertility Preservation in Female Cancer Patients
Executive Summary Purpse: T prvide health care prviders at Princess Margaret Cancer Centre infrmatin abut fertility preservatin ptins fr female cancer patients and recmmendatins fr care delivery. Methds:
More informationD E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y
D E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y 2 A B O U T This dcument prvides a summary f key findings fr the Derby, Derbyshire, Nttingham and
More informationVolume Measurement at CT
Vlume Measurement at CT Staging and Assessment f Respnse with Quantitative CT Lawrence Schwartz, MD Department f Radilgy Clumbia University Cllege f Physicians and Surgens LSCHWARTZ@COLUMBIA.EDU Recmmendatins
More informationApril 23, 2008 Information Sheet: Safety of BPA-derived Can Liners. Summary
April 23, 2008 Infrmatin Sheet: Safety f BPA-derived Can Liners Summary The use f bisphenl A (BPA)-derived epxy resins t make prtective catings fr metal fd and beverage packaging helps prvide safe, whlesme
More informationUrinary tract infection (lower) - women - Management
Urinary tract infectin (lwer) - wmen - Management Scenari: Cystitis in wmen wh are nt pregnant Hw shuld I manage a wman with suspected cystitis? Cnvey a psitive apprach and reassure the wman that cystitis
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationNutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:
Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin
More informationData Fusion for Predicting Breast Cancer Survival
Data Fusin fr Predicting Breast Cancer Linbailu Jiang, Yufei Zhang, Siyi Peng Mentr: Irene Kaplw December 11, 2015 1 Intrductin 1.1 Backgrund Cancer is mre f a severe health issue than ever in ur current
More informationBy Eleni Diamandidou, Aman U. Buzdar, Terry L. Smith, Debra Frye, Maria Witiaksono, and Gabriel N. Hortobagyi
Treatment-Related Leukemia in Breast Cancer Patients Treated With Flururacil-Dxrubicin- Cyclphsphamide Cmbinatin Adjuvant Chemtherapy: The University f Texas M.D. Andersn Cancer Center Experience By Eleni
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet n Fallpian Tube Cancer Intrductin The Fallpian tubes, als knwn as viducts, uterine tubes, and salpinges (singular salpinx) are tw very fine tubes lined
More information